Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes

Fig. 2

a mRNA expression analysis from human genome data in Genome Expression Analysis (GEO) data repository showing differential expression of SIRT2 mRNA between benign and primary PCa (p < 0.01) and between benign and metastasis (p = 0.004). b SIRT2 copy number alterations from Genomic Identification of Significant Targets in Cancer (GISTIC), showing the median and interquartile range of mRNA expression for SIRT2 in prostate cancer. There were 30 patients with SIRT2 deletions in the TCGA data base, including both shallow (n = 27) and deep (n = 3), which were compared to the 452 patients with diploid SIRT2. The mRNA expression levels were greater in the diploid compared to the deletion group. (p value = 0.03). c EP300 m RNA (gene for P300) expression shows a negative correlation with the mRNA expression of SIRT2. (Courtesy – TCGA database)

Back to article page